Non-small cell lung cancer continues to remain one of the main reasons behind cancer related deaths all across the world. Continuous studies and research works are going on that could help in…
Tag: Lung Cancer Drugs
Quratusugene Ozeplasmid for Small Cell Lung Cancer Receives Orphan Drug Designation by FDA
Genprex, Inc. is a clinical-stage gene therapy company and has announced the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to the drug, Reqorsa Immunogene Therapy (quratusugene…
Lung Cancer Drug, Osimertinib, Drastically Reduces Death Risk after Surgery
Lung cancer is among most common types of cancers in U.S. as well as around the world. According to the Centers for Disease Control and Prevention, it is responsible for nearly a…
FDA Approves Adjuvant Pembrolizumab for Non-Small Cell Lung Cancer Treatment
The US Food and Drug Administration has approved Pembrolizumab for adjuvant treatment following resection and platinum-based chemotherapy in patients with NSCLC (non-small cell lung cancer). This approval has been based on the…
U.S. FDA Approves Lung Cancer Drug, Adagrasib
The US Food and Drug Administration (FDA) has granted accelerated approval for Mirati Therapeutics’ Krazati (adagrasib) for treatment of mutated locally advanced or metastatic non-small cell lung cancer in adults. This accelerated…
FDA Grants Approval to Trastuzumab Deruxtecan for HER2 Lung Cancer
Lung cancer patients now have another treatment option. For those tumors carrying HER2 mutations, can now be treated with trastuzumab deruxtecan. This drug is already approved for use in HER2-positive breast cancer…
FDA Approves FoundationOne CDx in Non-Small Cell Lung Cancer
U.S. Food and Drug Administration (FDA) has approved the FoundationOne CDx as a companion diagnostic to guide treatment selection for patients with non-small cell lung cancer. This approval applies to the use…
FDA Approves Nivolumab Plus Chemo as Neoadjuvant Therapy for NSCLC Treatment
The FDA has approved nivolumab plus platinum-doublet chemotherapy for patients with non-small cell lung cancer in the neoadjuvant setting. Nivolumab is the first immune checkpoint inhibitor to get approval for resectable NSCLC….
European Commission Approves Pfizer’s Lorviqua for Advanced Lung Cancer Treatment
European Commission (EC) has granted marketing authorization for Lorviqua as monotherapy for treatment of patients with anaplastic lymphoma kinase (ALK) – positive advanced non-small cell lung cancer. Lorviqua is approved in US…
US FDA Approves Roche’s Tecentriq as Adjuvant Treatment for Early NSCLC
The US Food and Drug Administration (FDA) has approved Roche’s Tecentriq or atezolizumab as adjuvant treatment for patients with Stage II-IIIA non-small cell lung cancer (NSCLC) whose tumors express PD-L1=1%, as determined…
Combination of Experimental Drugs Shown to Extend Lung Cancer Survival in Mice
According to a new study led by researchers at NYU Grossman School of Medicine and its Laura and Isaac Perlmutter Cancer Center, a combination of experimental drugs has shown to extend survival…
FDA Approves First Targeted Therapy for Lung Cancer with Specific Genetic Mutation
The U.S. Food and Drug Administration has approved Lumakras (sotorasib) as first treatment for non-small cell lung cancer patients whose tumors have specific type of genetic mutation called KRAS G12C. It is…